Localization in a one-dimensional quasiperiodic Hamiltonian with off-diagonal disorder.

Vergés,Brey,Louis,Tejedor

DOI: https://doi.org/10.1103/PHYSREVB.35.5270

1987-04-01

Abstract:

What problem does this paper attempt to address?

Combination therapies induce cancer cell death through the integrated stress response and disturbed pyrimidine metabolism

Goetz Hartleben,Kenji Schorpp,Yun Kwon,Barbara Betz,Foivos-Filippos Tsokanos,Zahra Dantes,Arlett Schäfer,Ina Rothenaigner,José Manuel Monroy Kuhn,Pauline Morigny,Lisa Mehr,Sean Lin,Susanne Seitz,Janina Tokarz,Anna Artati,Jerzy Adamsky,Oliver Plettenburg,Dominik Lutter,Martin Irmler,Johannes Beckers,Maximilian Reichert,Kamyar Hadian,Anja Zeigerer,Stephan Herzig,Mauricio Berriel Diaz

DOI: https://doi.org/10.15252/emmm.202012461

2021-04-09

Abstract:By accentuating drug efficacy and impeding resistance mechanisms, combinatorial, multi-agent therapies have emerged as key approaches in the treatment of complex diseases, most notably cancer. Using high-throughput drug screens, we uncovered distinct metabolic vulnerabilities and thereby identified drug combinations synergistically causing a starvation-like lethal catabolic response in tumor cells from different cancer entities. Domperidone, a dopamine receptor antagonist, as well as several tricyclic antidepressants (TCAs), including imipramine, induced cancer cell death in combination with the mitochondrial uncoupler niclosamide ethanolamine (NEN) through activation of the integrated stress response pathway and the catabolic CLEAR network. Using transcriptome and metabolome analyses, we characterized a combinatorial response, mainly driven by the transcription factors CHOP and TFE3, which resulted in cell death through enhanced pyrimidine catabolism as well as reduced pyrimidine synthesis. Remarkably, the drug combinations sensitized human organoid cultures to the standard-of-care chemotherapy paclitaxel. Thus, our combinatorial approach could be clinically implemented into established treatment regimen, which would be further facilitated by the advantages of drug repurposing.
The Mevalonate Pathway, a Metabolic Target in Cancer Therapy

Borja Guerra,Carlota Recio,Haidée Aranda-Tavío,Miguel Guerra-Rodríguez,José M García-Castellano,Leandro Fernández-Pérez

DOI: https://doi.org/10.3389/fonc.2021.626971

2021-02-25

Abstract:A hallmark of cancer cells includes a metabolic reprograming that provides energy, the essential building blocks, and signaling required to maintain survival, rapid growth, metastasis, and drug resistance of many cancers. The influence of tumor microenviroment on cancer cells also results an essential driving force for cancer progression and drug resistance. Lipid-related enzymes, lipid-derived metabolites and/or signaling pathways linked to critical regulators of lipid metabolism can influence gene expression and chromatin remodeling, cellular differentiation, stress response pathways, or tumor microenviroment, and, collectively, drive tumor development. Reprograming of lipid metabolism includes a deregulated activity of mevalonate (MVA)/cholesterol biosynthetic pathway in specific cancer cells which, in comparison with normal cell counterparts, are dependent of the continuous availability of MVA/cholesterol-derived metabolites (i.e., sterols and non-sterol intermediates) for tumor development. Accordingly, there are increasing amount of data, from preclinical and epidemiological studies, that support an inverse association between the use of statins, potent inhibitors of MVA biosynthetic pathway, and mortality rate in specific cancers (e.g., colon, prostate, liver, breast, hematological malignances). In contrast, despite the tolerance and therapeutic efficacy shown by statins in cardiovascular disease, cancer treatment demands the use of relatively high doses of single statins for a prolonged period, thereby limiting this therapeutic strategy due to adverse effects. Clinically relevant, synergistic effects of tolerable doses of statins with conventional chemotherapy might enhance efficacy with lower doses of each drug and, probably, reduce adverse effects and resistance. In spite of that, clinical trials to identify combinatory therapies that improve therapeutic window are still a challenge. In the present review, we revisit molecular evidences showing that deregulated activity of MVA biosynthetic pathway has an essential role in oncogenesis and drug resistance, and the potential use of MVA pathway inhibitors to improve therapeutic window in cancer.
Screening of well-established drugs targeting cancer metabolism: reproducibility of the efficacy of a highly effective drug combination in mice.

Mohammad Abolhassani,Adeline Guais,Edward Sanders,Frédéric Campion,Iduna Fichtner,Jacques Bonte,Gianfranco Baronzio,Giammaria Fiorentini,Maurice Israël,Laurent Schwartz

DOI: https://doi.org/10.1007/s10637-011-9692-7

2011-06-09

Investigational New Drugs

Abstract:Alterations in metabolic pathways are known to characterize cancer. In order to suppress cancer growth, however, multiple proteins involved in these pathways have to be targeted simultaneously. We have developed a screening method to assess the best drug combination for cancer treatment based on targeting several factors implicated in tumor specific metabolism. Following a review of the literature, we identified those enzymes known to be deregulated in cancer and established a list of sixty-two drugs targeting them. These molecules are used routinely in clinical settings for diseases other than cancer. We screened a first library in vitro against four cell lines and then evaluated the most promising binary combinations in vivo against three murine syngeneic cancer models, (LL/2, Lewis lung carcinoma; B16-F10, melanoma; and MBT-2, bladder cancer). The optimum result was obtained using a combination of α-lipoic acid and hydroxycitrate (METABLOCTM). In this study, a third agent was added by in vivo evaluation of a large number of combinations. The addition of octreotide strongly reduced tumor development (T/C% value of 30.2 to 34.5%; P < 0.001) in the same models and prolonged animal survival (P < 0.001) as compared to cisplatin. These results were confirmed in a different laboratory setting using a human xenograft model (NCI-H69, small cell lung cancer). None of these three molecules are known to target DNA. The effectiveness of this combination in several animal models, as well as the low toxicity of these inexpensive drugs, emphasizes the necessity of rapidly setting up a clinical trial.

oncology,pharmacology & pharmacy
Abstract A056: Targeting the mevalonate biosynthesis pathway in gemcitabine resistant pancreatic cancer

Alica K. Beutel,Sabrina Calderon,Ethan Nghiem,Rima Singh,Cecily Anaraki,Kevin Gulay,Herve Tiriac,Alexander Kleger,Thomas Seufferlein,Alexander Muir,Cholsoon Jang,Dennis Juarez,David Fruman,Christopher Halbrook

DOI: https://doi.org/10.1158/1538-7445.panca2023-a056

IF: 11.2

2024-01-18

Cancer Research

Abstract:Pancreatic ductal adenocarcinoma (PDA) is a lethal malignancy with a low survival rate. A lack of durable responses to chemotherapy renders its treatment particularly challenging and largely contributes to the devastating prognosis. Gemcitabine, a pyrimidine anti-metabolite, is a cornerstone in PDA therapy, but resistance remains a major hurdle in clinical care. Multiple mechanisms of chemoresistance have been attributed to rewired metabolic pathways in PDA cells. Accordingly, we hypothesized that altered metabolism in gemcitabine resistance represents a therapeutic vulnerability that can be targeted to improve response to treatment. To investigate metabolic vulnerabilities in gemcitabine resistance, we generated gemcitabine resistant murine PDA cell lines and assembled patient-derived gemcitabine high versus low responder organoids. Transcriptomic profiling revealed a downregulation of the mevalonate biosynthesis pathway and its rate-limiting enzyme, HMG-CoA reductase, upon the acquisition of gemcitabine resistance. Upregulation of this pathway has been proposed as a primary resistance mechanism to statins, HMG-CoA reductase inhibitors that are frequently prescribed to treat patients with hyperlipidemia. Accordingly, we postulated that statins would be more potent in gemcitabine resistant PDA cells than in their sensitive counterparts. Indeed, resistant cells were exquisitely susceptible to inhibition of the mevalonate pathway, an observation consistent across multiple clinically available statins. Downstream rescue experiments suggested that the main impact of blocking the mevalonate biosynthesis pathway is through lowered levels of geranylgeranyl pyrophosphate and reduced protein geranylation. To validate our findings in vivo, we implanted gemcitabine resistant murine PDA cells into syngeneic mice that were fed with a modified diet precluding geranylgeraniol. Here, the treatment combination gemcitabine and pitavastatin inhibited tumor growth of resistant allografts. Collectively, these data suggest that targeting the HMG-CoA reductase is a metabolic vulnerability that is gained in PDA cells upon the acquisition of gemcitabine resistance. The combination therapy gemcitabine and pitavastatin, two widely used compounds in patients, has potential to translate into a clinical benefit and improve survival in this deadly disease. Citation Format: Alica K. Beutel, Sabrina Calderon, Ethan Nghiem, Rima Singh, Cecily Anaraki, Kevin Gulay, Herve Tiriac, Alexander Kleger, Thomas Seufferlein, Alexander Muir, Cholsoon Jang, Dennis Juarez, David Fruman, Christopher Halbrook. Targeting the mevalonate biosynthesis pathway in gemcitabine resistant pancreatic cancer [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Pancreatic Cancer; 2023 Sep 27-30; Boston, Massachusetts. Philadelphia (PA): AACR; Cancer Res 2024;84(2 Suppl) nr A056.

oncology
O -GlcNAcylation inhibition redirects the response of colon cancer cells to chemotherapy from senescence to apoptosis

Ingrid Loison,Adrien Pioger,Sonia Paget,Inès Metatla,OrgaRES Consortium,Christophe Mariette,Guillaume Piessen,François Corfiotti,Clarisse Eveno,François-René Pruvot,Stéphanie Truant,Mehdi El Amrani,Emmanuelle Leteurtre,Florence Renaud,Charlotte Dufour,Viviane Gnemmi,Laurence Wicquart,Fabienne Escande,Julie Leclerc,Isabelle Van Seuningen,Audrey Vincent,Corinne Abbadie,Vanessa Dehennaut

DOI: https://doi.org/10.1038/s41419-024-07131-5

2024-10-20

Cell Death and Disease

Abstract:The potential use of pro-senescence therapies, known as TIS (Therapy-Induced Senescence), for the treatment of colorectal cancer (CRC) generated significant interest since they require lower doses compared to those required for inducing apoptosis. However, the senescent cell cycle-arrested cancer cells are long-lived, and studies have revealed escape mechanisms contributing to tumor recurrence. To deepen our understanding of the survival pathways used by senescent cancer cells, we delved into the potential involvement of the hexosamine biosynthetic pathway (HBP). HBP provides UDP-GlcNAc, the substrate for O -GlcNAc transferase (OGT), which catalyzes O -GlcNAcylation, a post-translational modification implicated in regulating numerous cellular functions and aberrantly elevated in CRC. In this study, we demonstrated, in the p53-proficient colon cancer cell lines HCT116 and LS174T, that TIS induced by low-dose SN38 or etoposide treatment was accompanied with a decrease of GFAT (the rate limiting enzyme of the HBP), OGT and O -GlcNAcase (OGA) expression correlated with a slight reduction in O -GlcNAcylation levels. Further decreasing this level of O -GlcNAcylation by knocking-down GFAT or OGT redirected the cellular response to subtoxic chemotherapy doses from senescence to apoptosis, in correlation with an enhancement of DNA damages. Pharmacological inhibition of OGT with OSMI-4 in HCT116 and LS174T cells and in a patient-derived colon tumoroid model supported these findings. Taken together, these results suggest that combing O -GlcNAcylation inhibitors to low doses of conventional chemotherapeutic drugs could potentially reduce treatment side effects while preserving efficacy. Furthermore, this approach may increase treatment specificity, as CRC cells exhibit higher O -GlcNAcylation levels compared to normal tissues.

cell biology
Metabolic features of cancer cells impact immunosurveillance

Adrien Joseph,Pan Juncheng,Michele Mondini,Nizar Labaied,Mauro Loi,Julien Adam,Antoine Lafarge,Valentina Astesana,Florine Obrist,Christophe Klein,Norma Bloy,Gautier Stoll,Nicolas Signolle,Catherine Genestie,Diane Damotte,Marco Alifano,Alexandra Leary,Patricia Pautier,Philippe Morice,Sebastien Gouy,Eric Deutsch,Cyrus Chargari,Marie-Caroline Dieu-Nosjean,Isabelle Cremer,Judith Michels,Guido Kroemer,Maria Castedo

DOI: https://doi.org/10.1136/jitc-2021-002362

Abstract:Background: Tumors rewire their metabolism to achieve robust anabolism and resistance against therapeutic interventions like cisplatin treatment. For example, a prolonged exposure to cisplatin causes downregulation of pyridoxal kinase (PDXK), the enzyme that generates the active vitamin B6, and upregulation of poly ADP-ribose (PAR) polymerase-1 (PARP1) activity that requires a supply of nicotinamide (vitamin B3) adenine dinucleotide. We investigated the impact of the levels of PDXK and PAR on the local immunosurveillance (ie, density of the antigen presenting cells and adaptive immune response by CD8 T lymphocytes) in two different tumor types. Methods: Tumors from patients with locally advanced cervical carcinoma (LACC) and non-small cell lung cancer (NSCLC) were stained for PAR, PDXK, dendritic cell lysosomal associated membrane glycoprotein (DC-LAMP) and CD8 T cell infiltration. Their correlations and prognostic impact were assessed. Cisplatin-resistant NSCLC cell clones isolated from Lewis-lung cancer (LLC) cells were evaluated for PAR levels by immunoblot. Parental (PARlow) and cisplatin-resistant (PARhigh) clones were subcutaneously injected into the flank of C57BL/6 mice. Tumors were harvested to evaluate their immune infiltration by flow cytometry. Results: The infiltration of tumors by CD8 T and DC-LAMP+ cells was associated with a favorable overall survival in patients with LACC (p=0.006 and p=0.008, respectively) and NSCLC (p<0.001 for both CD8 T and DC-LAMP cells). We observed a positive correlation between PDXK expression and the infiltration by DC-LAMP (R=0.44, p=0.02 in LACC, R=0.14, p=0.057 in NSCLC), and a negative correlation between PAR levels and CD8 T lymphocytes (R=-0.39, p=0.034 in LACC, R=-0.18, p=0.017 in NSCLC). PARP1 is constitutively hyperactivated in cisplatin-resistant LLC cells manifesting elevated intracellular levels of poly(ADP-ribosyl)ated proteins (PARhigh). Tumors formed by such cancer cells injected into immunocompetent mice were scarcely infiltrated by CD8 T (p=0.028) and antigen presenting cells (p=0.086). Conclusions: Oncometabolic features can impact local immunosurveillance, providing new functional links between cisplatin resistance and therapeutic failure.
Genomics to select treatment for patients with metastatic breast cancer

Fabrice Andre,Thomas Filleron,Maud Kamal,Fernanda Mosele,Monica Arnedos,Florence Dalenc,Marie-Paule Sablin,Mario Campone,Hervé Bonnefoi,Claudia Lefeuvre-Plesse,William Jacot,Florence Coussy,Jean-Marc Ferrero,George Emile,Marie-Ange Mouret-Reynier,Jean-Christophe Thery,Nicolas Isambert,Alice Mege,Philippe Barthelemy,Benoit You,Nawale Hajjaji,Ludovic Lacroix,Etienne Rouleau,Alicia Tran-Dien,Sandrine Boyault,Valery Attignon,Pierre Gestraud,Nicolas Servant,Christophe Le Tourneau,Linda Larbi Cherif,Isabelle Soubeyran,Filippo Montemurro,Alain Morel,Amelie Lusque,Marta Jimenez,Alexandra Jacquet,Anthony Gonçalves,Thomas Bachelot,Ivan Bieche

DOI: https://doi.org/10.1038/s41586-022-05068-3

IF: 64.8

2022-09-09

Nature

Abstract:Cancer progression is driven in part by genomic alterations 1 . The genomic characterization of cancers has shown interpatient heterogeneity regarding driver alterations 2 , leading to the concept that generation of genomic profiling in patients with cancer could allow the selection of effective therapies 3,4 . Although DNA sequencing has been implemented in practice, it remains unclear how to use its results. A total of 1,462 patients with HER2-non-overexpressing metastatic breast cancer were enroled to receive genomic profiling in the SAFIR02-BREAST trial. Two hundred and thirty-eight of these patients were randomized in two trials (nos. NCT02299999 and NCT03386162) comparing the efficacy of maintenance treatment 5 with a targeted therapy matched to genomic alteration. Targeted therapies matched to genomics improves progression-free survival when genomic alterations are classified as level I/II according to the ESMO Scale for Clinical Actionability of Molecular Targets (ESCAT) 6 (adjusted hazards ratio (HR): 0.41, 90% confidence interval (CI): 0.27–0.61, P < 0.001), but not when alterations are unselected using ESCAT (adjusted HR: 0.77, 95% CI: 0.56–1.06, P = 0.109). No improvement in progression-free survival was observed in the targeted therapies arm (unadjusted HR: 1.15, 95% CI: 0.76–1.75) for patients presenting with ESCAT alteration beyond level I/II. Patients with germline BRCA1/2 mutations ( n = 49) derived high benefit from olaparib (g BRCA1 : HR = 0.36, 90% CI: 0.14–0.89; g BRCA2 : HR = 0.37, 90% CI: 0.17–0.78). This trial provides evidence that the treatment decision led by genomics should be driven by a framework of target actionability in patients with metastatic breast cancer.

multidisciplinary sciences
A transcriptome-based protein network that identifies new therapeutic targets in colorectal cancer

Stéphanie Durand,Killian Trillet,Arnaud Uguen,Aude Saint-Pierre,Catherine Le Jossic-Corcos,Laurent Corcos

DOI: https://doi.org/10.1186/s12864-017-4139-y

IF: 4.547

2017-09-30

BMC Genomics

Abstract:Background: Colon cancer occurrence is increasing worldwide, making it the third most frequent cancer. Although many therapeutic options are available and quite efficient at the early stages, survival is strongly decreased when the disease has spread to other organs. The identification of molecular markers of colon cancer is likely to help understanding its course and, eventually, to uncover novel genes to be targeted by drugs. In this study, we compared gene expression in a set of 95 human colon cancer samples to that in 19 normal colon mucosae, focusing on 401 genes from 5 selected pathways (Apoptosis, Cancer, Cholesterol metabolism and lipoprotein signaling, Drug metabolism, Wnt/beta-catenin). Deregulation of mRNA levels largely matched that of proteins, leading us to build in silico protein networks, starting from mRNA levels, to identify key proteins central to network activity. Results: Among the analyzed genes, 10.5% (42) had no reported link with colon cancer, including the SFRP1, IGF1 and ADH1B (down), and MYC and IL8 (up), whose encoded proteins were most interacting with other proteins from the same or even distinct networks. Analyzing all pathways globally led us to uncover novel functional links between a priori unrelated or rather remotely connected pathways, such as the Drug metabolism and the Cancer pathways or, even more strikingly, between the Cholesterol metabolism and lipoprotein signaling and the Cancer pathways. In addition, we analyzed the responsiveness of some of the deregulated genes essential to network activities, to chemotherapeutic agents used alone or in presence of Lovastatin, a lipid-lowering drug. Some of these treatments could oppose the deregulations occurring in cancer samples, including those of the CHECK2, CYP51A1, HMGCS1, ITGA2, NME1 or VEGFA genes. Conclusions: Our network-based approach allowed discovering genes not previously known to play regulatory roles in colon cancer. Our results also showed that selected drug treatments might revert the cancer-specific deregulation of genes playing prominent roles within the networks operating to maintain colon homeostasis. Among those genes, some could constitute novel testable targets to eliminate colon cancer cells, either directly or, potentially, through the use of lipid-lowering drugs such as statins, in association with selected anticancer drugs.
Targeting tumor cell metabolism with statins

J W Clendening,L Z Penn

DOI: https://doi.org/10.1038/onc.2012.6

IF: 8.756

2012-02-06

Oncogene

Abstract:The mevalonate pathway is a core biochemical process, crucial for the generation of cholesterol and other key metabolic end products. The rate-limiting enzyme of the mevalonate pathway, hydroxymethylglutaryl coenzyme A reductase (HMGCR), is safely and effectively targeted by the statin family of inhibitors to treat hypercholesterolemia. The anticancer activity of statins has also been widely reported, yet the tumor-selective mechanisms that mediate these antiproliferative effects remain largely unclear. The importance of altered metabolism in the context of tumorigenesis has received renewed attention as metabolic changes entwined with the molecular hallmarks of cancer have been elucidated. Although several metabolic pathways have been linked to cancer progression and etiology, it was only recently that HMGCR and the mevalonate pathway were also shown to have a distinct role in cellular transformation. In this review, we chart the historical progression of statins from cholesterol-lowering blockbusters to anticancer agents with imminent potential, and further discuss an emerging role for HMGCR and the mevalonate pathway in the metabolic reprogramming of cancer.

oncology,genetics & heredity,biochemistry & molecular biology,cell biology
Conditional lethality profiling reveals anticancer mechanisms of action and drug-nutrient interactions

Kyle M. Flickinger,Kelli M. Wilson,Nicholas J. Rossiter,Andrea L. Hunger,Paresh V. Vishwasrao,Tobie D. Lee,Carlos A. Mellado Fritz,Rebecca M. Richards,Matthew D. Hall,Jason R. Cantor

DOI: https://doi.org/10.1126/sciadv.adq3591

IF: 13.6

2024-10-05

Science Advances

Abstract:Chemical screens across hundreds of cell lines have shown that the drug sensitivities of human cancers can vary by genotype or lineage. However, most drug discovery studies have relied on culture media that poorly reflect metabolite levels in human blood. Here, we perform drug screens in traditional and Human Plasma–Like Medium (HPLM). Sets of compounds that show conditional anticancer activity span different phases of global development and include non-oncology drugs. Comparisons of the synthetic and serum-derived components that comprise typical media trace sets of conditional phenotypes to nucleotide synthesis substrates. We also characterize a unique dual mechanism for brivudine, a compound approved for antiviral use. Brivudine selectively impairs cell growth in low folate conditions by targeting two enzymes involved in one-carbon metabolism. Cataloged gene essentiality data further suggest that conditional phenotypes for other compounds are linked to off-target effects. Our findings establish general strategies for identifying drug-nutrient interactions and mechanisms of action by exploiting conditional lethality in cancer cells.

multidisciplinary sciences
Evaluating synergistic effects of metformin and simvastatin on ovarian cancer cells

Sara Mikhael,Abdullah Kurdi,Nathalie Khoueiry-Zgheib,Roula Tahtouh,Rihab Nasr,George Hilal

DOI: https://doi.org/10.1371/journal.pone.0298127

IF: 3.7

2024-03-15

PLoS ONE

Abstract:Background Ovarian Cancer (OC) stands as the most lethal gynecological malignancy, presenting an urgent clinical challenge in the quest to improve response rates. One approach to address this challenge is through drug repurposing, exemplified by the investigation of metabolic-modulating drugs such as Metformin (MTF) and Simvastatin (SIM). This study aims to explore the molecular mechanisms contributing to the potential synergistic anti-cancer effects between MTF and SIM on ovarian cancer cells. Methods We assessed the effects of the combination on the proliferation and viability of two cell lines OVCAR-3 and SKOV-3. IC50 concentrations of MTF and SIM were determined using a proliferation assay, followed by subtoxic concentrations to explore the potential synergistic effects on the viability of both cell lines. Transcriptomic analysis was conducted on OVCAR-3 treated cells, and the findings were validated by assessing the expression levels of differentially expressed genes (DEGs) through real-time PCR in both cell lines SK-OV-3 and OVCAR-3. Results Cytotoxicity analysis guided the selection of treatment concentrations as such MTF 10 mM and SIM 5 μM. The combined treatment of MTF and SIM demonstrated a synergistic inhibition of proliferation and viability in both cell lines. In OVCAR-3, exclusive identification of 507 DEGs was seen in the combination arm. Upregulation of FOXO3, RhoA, and TNFα, along with downregulation of PIK3R1, SKP2, and ATP6V1D levels, was observed in OVCAR-3 treated cells. Real-time PCR validation confirmed the consistency of expression levels for the mentioned DEGs. Conclusion Our data strongly supports the presence of synergy between MTF and SIM in OC cells. The combination’s effect is associated with the dysregulation of genes in the key regulators AMPK and mTOR alongside other interconnected pathways.

multidisciplinary sciences
Multi-Omics Analysis of NCI-60 Cell Line Data Reveals Novel Metabolic Processes Linked with Resistance to Alkylating Anti-Cancer Agents

Blake R. Rushing

DOI: https://doi.org/10.3390/ijms241713242

IF: 5.6

2023-08-27

International Journal of Molecular Sciences

Abstract:This study aimed to elucidate the molecular determinants influencing the response of cancer cells to alkylating agents, a major class of chemotherapeutic drugs used in cancer treatment. The study utilized data from the National Cancer Institute (NCI)-60 cell line screening program and employed a comprehensive multi-omics approach integrating transcriptomic, proteomic, metabolomic, and SNP data. Through integrated pathway analysis, the study identified key metabolic pathways, such as cysteine and methionine metabolism, starch and sucrose metabolism, pyrimidine metabolism, and purine metabolism, that differentiate drug-sensitive and drug-resistant cancer cells. The analysis also revealed potential druggable targets within these pathways. Furthermore, copy number variant (CNV) analysis, derived from SNP data, between sensitive and resistant cells identified notable differences in genes associated with metabolic changes (WWOX, CNTN5, DDAH1, PGR), protein trafficking (ARL17B, VAT1L), and miRNAs (MIR1302-2, MIR3163, MIR1244-3, MIR1302-9). The findings of this study provide a holistic view of the molecular landscape and dysregulated pathways underlying the response of cancer cells to alkylating agents. The insights gained from this research can contribute to the development of more effective therapeutic strategies and personalized treatment approaches, ultimately improving patient outcomes in cancer treatment.

biochemistry & molecular biology,chemistry, multidisciplinary
Mild prenatal stress in rats is associated with enhanced conditioned fear

W. Griffin,H. Skinner,A. Salm,D. Birkle

DOI: https://doi.org/10.1016/S0031-9384(03)00097-0

2003-07-01

Abstract:
The present state and future of laminitis research.

J. Belknap,Raymond J. Geor

DOI: https://doi.org/10.1111/j.2042-3306.2012.00669.x

IF: 2.692

2012-11-01

Equine Veterinary Journal

Abstract:(AAEP) to related to the epidemiology of laminitis. a practice-based survey of prognosis in pasture-based laminitis as part of their Evidence-Based Medicine and colleagues are completing a study in the United Kingdom, while the AAEP Research Foundation has initiated a case–control study of acute endocrinopathic laminitis in the United States. Additionally, planning is underway for a case–control study on supporting limb laminitis. We anticipate that the results on these studies will more clearly identify risk factors for laminitis and pave the way for further studies on the pathogenesis, treatment and prevention of this crippling condition.
Integration of transcriptomics, proteomics, and metabolomics data to reveal HER2-associated metabolic heterogeneity in gastric cancer with response to immunotherapy and neoadjuvant chemotherapy

Qihang Yuan,Dawei Deng,Chen Pan,Jie Ren,Tianfu Wei,Zeming Wu,Biao Zhang,Shuang Li,Peiyuan Yin,Dong Shang

DOI: https://doi.org/10.3389/fimmu.2022.951137

IF: 7.3

2022-08-04

Frontiers in Immunology

Abstract:Background Currently available prognostic tools and focused therapeutic methods result in unsatisfactory treatment of gastric cancer (GC). A deeper understanding of human epidermal growth factor receptor 2 (HER2)-coexpressed metabolic pathways may offer novel insights into tumour-intrinsic precision medicine. Methods The integrated multi-omics strategies (including transcriptomics, proteomics and metabolomics) were applied to develop a novel metabolic classifier for gastric cancer. We integrated TCGA-STAD cohort (375 GC samples and 56753 genes) and TCPA-STAD cohort (392 GC samples and 218 proteins), and rated them as transcriptomics and proteomics data, resepectively. 224 matched blood samples of GC patients and healthy individuals were collected to carry out untargeted metabolomics analysis. Results In this study, pan-cancer analysis highlighted the crucial role of ERBB2 in the immune microenvironment and metabolic remodelling. In addition, the metabolic landscape of GC indicated that alanine, aspartate and glutamate (AAG) metabolism was significantly associated with the prevalence and progression of GC. Weighted metabolite correlation network analysis revealed that glycolysis/gluconeogenesis (GG) and AAG metabolism served as HER2-coexpressed metabolic pathways. Consensus clustering was used to stratify patients with GC into four subtypes with different metabolic characteristics (i.e. quiescent, GG, AAG and mixed subtypes). The GG subtype was characterised by a lower level of ERBB2 expression, a higher proportion of the inflammatory phenotype and the worst prognosis. However, contradictory features were found in the mixed subtype with the best prognosis. The GG and mixed subtypes were found to be highly sensitive to chemotherapy, whereas the quiescent and AAG subtypes were more likely to benefit from immunotherapy. Conclusions Transcriptomic and proteomic analyses highlighted the close association of HER-2 level with the immune status and metabolic features of patients with GC. Metabolomics analysis highlighted the co-expressed relationship between alanine, aspartate and glutamate and glycolysis/gluconeogenesis metabolisms and HER2 level in GC. The novel integrated multi-omics strategy used in this study may facilitate the development of a more tailored approach to GC therapy.

immunology
Importance of excessive ethanol ingestion in the patient with suspected drink spiking

D. Wells,Maureen Phillips

DOI: https://doi.org/10.1111/j.1742-6723.2009.01177.x

2009-06-01

Emergency Medicine Australasia

Abstract:The covert administration of a drug for the purpose of altering another person’s conscious state is not a new phenomenon. Drugging another for some form of personal gain (particularly property and sexual crimes) has been documented for many centuries. Drink spiking in the form of the addition of ‘knock out drops’ to alcoholic beverages gained notoriety in 1903 when Chicago bartender Mickey Finn of the Lone Star Saloon was accused of using chloral hydrate to incapacitate clientele before robbing them. Testimony at his trial was given by prostitute ‘Gold Tooth’ Mary Thornton, who described the victims being drugged, escorted to a back room, robbed and dumped in the alley where they would wake with no recollection of events. The term ‘Mickey Finn’ or ‘slipping a mickey’ came into usage in about 1915 to describe the act of surreptitiously adding a sedative to someone’s drink. The concept has been employed in the plots of numerous novels and films from comedies and cartoons, such as I Love Lucy and Daffy Duck in the 1960’s, through to James Bond and the more recent escapades of Seinfeld and House. The topic of covert drug administration, including drink spiking, has received considerable attention in the lay press in recent times. This reporting and much subsequent discussion have been characterized by an absence of scientific information and a lack of balance. This has resulted in widespread misperception about the frequency of these events and a failure to acknowledge and address significant public health issues. In the early 2000s, community awareness advertising campaigns in Australia escalated public concern about the frequency and dangers of drink spiking, and described the actions that should be taken to minimize the risk. Young people were informed in media campaigns targeted at youth and supported by the Australian government and the Australian Federal Police about the types of drugs that were being used in drink spiking, including alcohol, prescription items and illicit drugs particularly benzodiazepines, barbiturates, hypnotics and gamma-hydroxybutyrate. Recommendations to prevent drink spiking included people buying and guarding their own drinks, and seeking medical attention if symptoms developed after ingesting a drink suspected of being spiked. In fairness to the intentions of such campaigns, there was little objective information from clinical toxicological trials and many anecdotal accounts in the media to support concern about drink spiking in the context of allegations of sexual assault. In West Australia, the police conducted a campaign to raise awareness of drink spiking and to encourage suspected victims to attend hospital ED.
Integrated Metabolite and Gene Expression Profiles Identify Lipid Biomarkers Associated with Progression of Hepatocellular Carcinoma and Patient Outcomes

Anuradha Budhu,Stephanie Roessler,Xuelian Zhao,Zhipeng Yu,Marshonna Forgues,Junfang Ji,Edward Karoly,Lun-Xiu Qin,Qing-Hai Ye,Hu-Liang Jia,Jia Fan,Hui-Chuan Sun,Zhao-You Tang,Xin Wei Wang

DOI: https://doi.org/10.1053/j.gastro.2013.01.054

IF: 29.4

2013-01-01

Gastroenterology

Abstract:BACKGROUND & AIMS: We combined gene expression and metabolic profiling analyses to identify factors associated with outcomes of patients with hepatocellular carcinoma (HCC). METHODS: We compared metabolic and gene expression patterns between paired tumor and nontumor tissues from 30 patients with HCC, and validated the results using samples from 356 patients with HCC. A total of 469 metabolites were measured using liquid chromatography/mass spectrometry and gas chromatography/mass spectrometry. Metabolic and genomic data were integrated, and Kaplan-Meier and Cox proportional hazards analyses were used to associate specific patterns with patient outcomes. Associated factors were evaluated for their effects on cancer cells in vitro and tumor formation in nude mice. RESULTS: We identified 28 metabolites and 169 genes associated with aggressive HCC. Lipid metabolites of stearoyl-CoA-desaturase (SCD) activity were associated with aberrant palmitate signaling in aggressive HCC samples. Expression of gene products associated with these metabolites, including SCD, were associated independently with survival times and tumor recurrence in the test and validation sets. Combined expression of SCD and alpha-fetoprotein were associated with outcomes of patients with early-stage HCC. Levels of monounsaturated palmitic acid, the product of SCD activity, were increased in aggressive HCCs; monounsaturated palmitic acid increased migration and invasion of cultured HCC cells and colony formation by HCC cells. HCC cells that expressed small interfering RNA against SCD had decreased cell migration and colony formation in culture and reduced tumorigenicity in mice. CONCLUSIONS: By using a combination of gene expression and metabolic profile analysis, we identified a lipogenic network that involves SCD and palmitate signaling and was associated with HCC progression and patient outcomes. The microarray platform and data have been submitted to the Gene Expression Omnibus public database at NCBI following MIAME guidelines. Accession numbers: GPL4700 (platform), and GSE6857 (samples).
Identification of microenvironment features associated with primary resistance to anti-PD-1/PD-L1 + antiangiogenesis in gastric cancer through spatial transcriptomics and plasma proteomics

Sophie Cousin,Jean-Philippe Guégan,Kohei Shitara,Lola Jade Palmieri,Jean Philippe Metges,Simon Pernot,Shota Fukuoka,Shohei Koyama,Hiroyoshi Nishikawa,Carine A. Bellera,Antoine Adenis,Carlos A. Gomez-Roca,Philippe Alexandre Cassier,Antoine Hollebecque,Coralie Cantarel,Michèle Kind,Isabelle Soubeyran,Lucile Vanhersecke,Alban Bessede,Antoine Italiano

DOI: https://doi.org/10.1186/s12943-024-02092-x

IF: 37.3

2024-09-15

Molecular Cancer

Abstract:Anti-angiogenic agents elicit considerable immune modulatory effects within the tumor microenvironment, underscoring the rationale for synergistic clinical development of VEGF and immune checkpoint inhibitors in advanced gastric cancer (AGC). Early phase studies involving Asian patients demonstrated encouraging anti-tumor efficacies. We report the results of the REGOMUNE phase II study, in which Caucasian patients were administered regorafenib, a multi-tyrosine kinase inhibitor, in combination with avelumab, a PD-L1-targeting monoclonal antibody. This therapeutic regimen resulted in deep and durable responses in 19% of patients, with the median duration of response not yet reached. Notwithstanding, a significant proportion of AGC patients exhibited no therapeutic advantage, prompting investigations into mechanisms of inherent resistance. Comprehensive biomarker profiling elucidated that non-responders predominantly exhibited an augmented presence of M2 macrophages within the tumor microenvironment and a marked overexpression of S100A10 by neoplastic cells, a protein previously implicated in macrophage chemotaxis. Additionally, peripheral biomarker assessments identified elevated levels of cytokines, including CSF-1, IL-4, IL-8, and TWEAK, correlating with adverse clinical outcomes, thereby accentuating the role of macrophage infiltration in mediating resistance. These insights furnish an invaluable foundation for elucidating, and potentially circumventing, resistance mechanisms in current AGC therapeutic paradigms, emphasizing the integral role of tumor microenvironmental dynamics and immune modulation.

oncology,biochemistry & molecular biology
Metagenomic analysis during capecitabine therapy reveals microbial chemoprotective mechanisms and predicts drug toxicity in colorectal cancer patients

Lars E Hillege,Kai R Trepka,Janine Ziemons,Romy Aarnoutse,Benjamin GH Guthrie,Judith de Vos-Geelen,Liselot Valkenburg-van Iersel,Irene EG van Hellemond,Arnold Baars,Johanna HMJ Vestjens,John Penders,Adam Deutschbauer,Chloe E Atreya,Wesley A Kidder,Peter J Turnbaugh,Marjolein L Smidt

DOI: https://doi.org/10.1101/2024.10.11.24315249

2024-10-15

Abstract:Purpose. Unpredictable chemotherapy side effects are a major barrier to successful treatment. Cell culture and mouse experiments indicate that the gut microbiota is influenced by and influences anti-cancer drugs. However, metagenomic data from patients paired to careful side effect monitoring remains limited. Herein, we focus on the oral fluoropyrimidine capecitabine (CAP). We investigate CAP-microbiome interactions through metagenomic sequencing of longitudinal stool sampling from a cohort of advanced colorectal cancer (CRC) patients. Methods. We established a prospective cohort study including 56 patients with advanced CRC treated with CAP monotherapy across 4 centers in the Netherlands. Stool samples and clinical questionnaires were collected at baseline, during cycle 3, and post-treatment. Metagenomic sequencing to assess microbial community structure and gene abundance was paired with transposon mutagenesis, targeted gene deletion, and media supplementation experiments. An independent US cohort was used for model validation. Results. CAP treatment significantly altered gut microbial composition and pathway abundance, enriching for menaquinol (vitamin K2) biosynthesis genes. Transposon library screens, targeted gene deletions, and media supplementation confirmed that menaquinol biosynthesis protects Escherichia coli from drug toxicity. Microbial menaquinol biosynthesis genes were associated with decreased peripheral sensory neuropathy. Machine learning models trained in this cohort predicted hand-foot syndrome and dose reductions in an independent cohort. Conclusion. These results suggest treatment-associated increases in microbial vitamin biosynthesis serve a chemoprotective role for bacterial and host cells, with implications for toxicities outside the gastrointestinal tract. We provide a proof-of-concept for the use of microbiome profiling and machine learning to predict drug toxicities across independent cohorts. These observations provide a foundation for future human intervention studies, more in-depth mechanistic dissection in preclinical models, and extension to other cancer treatments.
Integrative single-cell and bulk transcriptomes analyses reveals heterogeneity of serine-glycine-one-carbon metabolism with distinct prognoses and therapeutic vulnerabilities in HNSCC

Lixuan Wang,Rongchun Yang,Yue Kong,Jing Zhou,Yingyao Chen,Rui Li,Chuwen Chen,Xinran Tang,Xiaobing Chen,Juan Xia,Xijuan Chen,Bin Cheng,Xianyue Ren

DOI: https://doi.org/10.1038/s41368-024-00310-2

IF: 24.897

2024-06-17

International Journal of Oral Science

Abstract:Metabolic heterogeneity plays a central role in sustaining uncontrolled cancer cell proliferation and shaping the tumor microenvironment (TME), which significantly compromises the clinical outcomes and responses to therapy in head and neck squamous cell carcinoma (HNSCC) patients. This highlights the urgent need to delineate the intrinsic heterogeneity and biological roles of metabolic vulnerabilities to advance precision oncology. The metabolic heterogeneity of malignant cells was identified using single-cell RNA sequencing (scRNA-seq) profiles and validated through bulk transcriptomes. Serine–glycine-one-carbon (SGOC) metabolism was screened out to be responsible for the aggressive malignant properties and poor prognosis in HNSCC patients. A 4-SGOC gene prognostic signature, constructed by LASSO-COX regression analysis, demonstrated good predictive performance for overall survival and therapeutic responses. Patients in the low-risk group exhibited greater infiltration of exhausted CD8 + T cells, and demonstrated better clinical outcomes after receiving immunotherapy and chemotherapy. Conversely, high-risk patients exhibited characteristics of cold tumors, with enhanced IMPDH1-mediated purine biosynthesis, resulting in poor responses to current therapies. IMPDH1 emerged as a potential therapeutic metabolic target. Treatment with IMPDH inhibitors effectively suppressed HNSCC cell proliferation and metastasis and induced apoptosis in vitro and in vivo by triggering GTP-exhaustion nucleolar stress. Our findings underscore the metabolic vulnerabilities of HNSCC in facilitating accurate patient stratification and individualized precise metabolic-targeted treatment.

dentistry, oral surgery & medicine

Localization in a one-dimensional quasiperiodic Hamiltonian with off-diagonal disorder.

Combination therapies induce cancer cell death through the integrated stress response and disturbed pyrimidine metabolism

The Mevalonate Pathway, a Metabolic Target in Cancer Therapy

Screening of well-established drugs targeting cancer metabolism: reproducibility of the efficacy of a highly effective drug combination in mice.

Abstract A056: Targeting the mevalonate biosynthesis pathway in gemcitabine resistant pancreatic cancer

O -GlcNAcylation inhibition redirects the response of colon cancer cells to chemotherapy from senescence to apoptosis

Metabolic features of cancer cells impact immunosurveillance

Genomics to select treatment for patients with metastatic breast cancer

A transcriptome-based protein network that identifies new therapeutic targets in colorectal cancer

Targeting tumor cell metabolism with statins

Conditional lethality profiling reveals anticancer mechanisms of action and drug-nutrient interactions

Evaluating synergistic effects of metformin and simvastatin on ovarian cancer cells

Multi-Omics Analysis of NCI-60 Cell Line Data Reveals Novel Metabolic Processes Linked with Resistance to Alkylating Anti-Cancer Agents

Mild prenatal stress in rats is associated with enhanced conditioned fear

The present state and future of laminitis research.

Integration of transcriptomics, proteomics, and metabolomics data to reveal HER2-associated metabolic heterogeneity in gastric cancer with response to immunotherapy and neoadjuvant chemotherapy

Importance of excessive ethanol ingestion in the patient with suspected drink spiking

Integrated Metabolite and Gene Expression Profiles Identify Lipid Biomarkers Associated with Progression of Hepatocellular Carcinoma and Patient Outcomes

Identification of microenvironment features associated with primary resistance to anti-PD-1/PD-L1 + antiangiogenesis in gastric cancer through spatial transcriptomics and plasma proteomics

Metagenomic analysis during capecitabine therapy reveals microbial chemoprotective mechanisms and predicts drug toxicity in colorectal cancer patients

Integrative single-cell and bulk transcriptomes analyses reveals heterogeneity of serine-glycine-one-carbon metabolism with distinct prognoses and therapeutic vulnerabilities in HNSCC